Abstract A041: KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer
KRAS is the dominant oncogene in pancreatic ductal adenocarcinoma (PDAC), mutated in ∼90% of tumors, and required for tumor initiation and tumor maintenance. The overall 5-year survival rate of PDAC remains a dismal ∼10%, underscoring an unmet need to develop novel therapies to ultimately improve patients’ outcomes....